HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?

Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

(2016) David C. Boettiger et al.   AIDS

Potential Roles of Protease Inhibitors in Cancer Progression

(2016) Peng Yang et al.   Asian Pacific Journal of Cancer Prevention

Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells

(2016) Geetika Chakravarty et al.   BIOCHIMIE

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer

(2016) E. J. Hill et al.   CLINICAL CANCER RESEARCH

A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease

(2016) Lynne Hampson et al.   PLoS One

Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway

(2015) Tong Xiang et al.   CANCER LETTERS

Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity

(2015) Ruchi Singh et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

(2015) C. Driessen et al.   HAEMATOLOGICA

The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K

(2015) Danijela Maksimovic-Ivanic et al.   LEUKEMIA RESEARCH

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

(2015) C. Driessen et al.   HAEMATOLOGICA

A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors

(2015) Gideon M. Blumenthal et al.   Oncotarget

Anticancer Effects of the Nitric Oxide-Modified Saquinavir Derivative Saquinavir-NO against Multidrug-Resistant Cancer Cells

(2015) Florian Rothweiler et al.   NEOPLASIA

Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy

(2014) Joell J. Gills et al.   Autophagy

Perspective of Humanized Mouse Models for Assessing PK/PD and Toxic Profile of Drug Candidates in Preclinical Study

(2014) Kan Chiba   Drug Metabolism and Pharmacokinetics

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

(2014) Andrew C. Hoover et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

The HIV Protease Inhibitor Nelfinavir Down-Regulates RET Signaling and Induces Apoptosis in Medullary Thyroid Cancer Cells

(2014) Yevgeniya Kushchayeva et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy

(2014) Soren Gantt et al.   JOURNAL OF CLINICAL VIROLOGY

Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells

(2014) Aditi Mathur et al.   PLoS One

The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro

(2013) Riccardo Adamo et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme

(2013) Michelle Alonso-Basanta et al.   JOURNAL OF NEURO-ONCOLOGY

Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis

(2013) Filip Petković et al.   JOURNAL OF NEUROIMMUNOLOGY

Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations

(2013) Marianne Kraus et al.   LEUKEMIA RESEARCH

Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer

(2013) Jeroen Buijsen et al.   RADIOTHERAPY AND ONCOLOGY

Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential

(2013) C Y Darini et al.   Cell Death & Disease

Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity

(2012) Giovanni Barillari et al.   AIDS

Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy

(2012) S. K. McBrayer et al.   BLOOD

Phase I study of nelfinavir in liposarcoma

(2012) Janet Pan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL

(2012) Marija Mojic et al.   CELL CYCLE

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo

(2012) C. Bono et al.   HAEMATOLOGICA

Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir

(2012) Joong Sup Shim et al.   JNCI-Journal of the National Cancer Institute

A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response

(2012) Ramesh Rengan et al.   Journal of Thoracic Oncology

The HIV Protease Inhibitor Nelfinavir Inhibits Kaposi's Sarcoma-Associated Herpesvirus Replication In Vitro

(2011) Soren Gantt et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The new and less toxic protease inhibitor saquinavir–NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir

(2011) Filippo Canducci et al.   ANTIVIRAL RESEARCH

Nelfinavir induces radiation sensitization in pituitary adenoma cells

(2011) Jing Zeng et al.   CANCER BIOLOGY & THERAPY

In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

(2011) Marco Donia et al.   CELL CYCLE

CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy

(2010) Jianlan You et al.   CANCER SCIENCE

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

(2010) R. J. Kimple et al.   CLINICAL CANCER RESEARCH

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases

(2010) Elena Toschi et al.   INTERNATIONAL JOURNAL OF CANCER

Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells

(2010) Sanja Mijatovic et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas

(2010) Manmeet S. Ahluwalia et al.   JOURNAL OF NEURO-ONCOLOGY

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

(2010) Monique Maas et al.   LANCET ONCOLOGY

Clinical course of classic Kaposiʼs sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

(2009) Paolo Monini et al.   AIDS

Montelukast Is a Potent and Durable Inhibitor of Multidrug Resistance Protein 2-Mediated Efflux of Taxol and Saquinavir

(2009) Upal Roy et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells

(2009) Karen McLean et al.   GYNECOLOGIC ONCOLOGY

NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts

(2008) N. Ouyang et al.   CARCINOGENESIS

The potential of proteasome inhibitors in cancer therapy

(2008) Jan Sterz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells

(2008) Md. Zahidunnabi Dewan et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer

(2008) Thomas B. Brunner et al.   JOURNAL OF CLINICAL ONCOLOGY

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

(2008) Anna Bratasz et al.   Journal of Translational Medicine

Anti-HIV drugs for cancer therapeutics: back to the future?

(2008) Warren A Chow et al.   LANCET ONCOLOGY

Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo

(2008) D. Maksimovic-Ivanic et al.   MOLECULAR CANCER THERAPEUTICS

Anti-Inflammatory, Antiproliferative, and Cytoprotective Activity of NO Chimera Nitrates of Use in Cancer Chemoprevention

(2008) G. K. Hagos et al.   MOLECULAR PHARMACOLOGY

Repositioning HIV protease inhibitors as cancer therapeutics

(2008) Wendy B Bernstein et al.   Current Opinion in HIV and AIDS